Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A study looking at chemotherapy and biological therapy for lymphoma of the brain or spinal cord (TIER)
This study is looking at a new combination of cancer drugs for primary central nervous system lymphoma. Central nervous system lymphoma is called CNS lymphoma for short. It is a cancer of the
More about this trial
CNS lymphoma is usually a type of non Hodgkin lymphoma called diffuse large B cell lymphoma (DLBCL). It is a type of high grade lymphoma. High grade lymphomas generally grow more quickly than low grade lymphomas.
Doctors often treat CNS lymphoma with chemotherapy. Sometimes the lymphoma does not respond to chemotherapy or it comes back after treatment. In this situation there is no
The aims of the study are to
- Discover the best dose of thiotepa
- See how well the combination of thiotepa, ifosfamide, etoposide and rituximab works for CNS lymphoma
Who can enter
You may be able to join this study if all of the following apply. You
- Have diffuse large B cell lymphoma that started in your brain and spinal cord has come back after previous treatment or has not responded to treatment
- Have had at least 1 or 2 chemotherapy treatments that included the drug methotrexate
- Have satisfactory blood test results
- Have satisfactory heart and lung test results
- Are well enough to be up and about for at least half the day (performance status 0, 1 or 2)
- Are able to have MRI scans
- Are able to have CT or PET-CT scans
- Are willing to use reliable contraception for a month before starting treatment and for 12 months afterwards if there is any chance you or your partner could become pregnant
- Are at least 16 years old
You cannot join this study if any of these apply. You
- Have lymphoma anywhere in your body other than your brain and spinal cord
- Have had chemotherapy in the last 4 weeks
- Have had radiotherapy to your brain in the last 6 months
- Have had a stem cell transplant in the last 12 months and the treatment included the drug thiotepa
- Have had previous treatment with the combination of the drugs rituximab, ifosfamide and etoposide (R-IE) in the last year
- Have a long term or current infection that needs treatment with antibiotics
- Are known to be HIV or hepatitis C positive
- Have hepatitis B infection
- Are pregnant or breastfeeding
This study is in 2 parts and is called a phase 1/ 2 study. Doctors need around 40 people to take part. In the first part of the study (phase 1), the study team are looking at the maximum safe dose of thiotepa they can give when it is used in combination with ifosfamide, etoposide and rituximab. This part of the trial has now closed.
The second part of the trial (phase 2) is now open. It will look at how well the treatment works.
You have treatment every 3 weeks. Each 3 week period is called a cycle of treatment. You have 2 cycles. After this your doctor will decide if you should have another 1 or 2 cycles.
You have all of the drugs through a drip into a vein (intravenously). You have them over 5 days.
- On day 1 you have rituximab
- On day 2 you have etoposide, ifosfamide and rituximab
- On day 3 you have ifosfamide
- On day 4 you have ifosfamide
- On day 5 you have thiotepa
Some people can have a reaction to rituximab causing flu like symptoms such as a fever, chills and shivering (rigors), a headache and feeling sick. If you have a reaction to the rituximab on day 1 the second dose may be delayed to day 3 or 4.
Most people will have their treatment as an inpatient in hospital but if you are well enough you could have the treatment as an outpatient. If you have treatment as an outpatient, each visit will take between 2 to 6 hours.
The study team will ask for some extra samples of blood that would be taken at the same time as other blood tests. They will also ask for samples of your lymphoma that was removed when you had a biopsy. This would be from when your lymphoma was first diagnosed and when it came back or when treatment stopped working. You would not need to have an additional biopsy.
If you don’t want to give these samples for research, you don’t have to. You can still take part in the study.
You see the study team and have some tests before you start treatment. These may include
- Physical examination
- Blood tests
- Eye tests
- A neurological assessment (the doctor will ask a series of questions and ask you to do a few simple exercises)
- MRI scan of your brain and spine
- PET-CT scan or CT scan of your neck, chest, tummy (abdomen), and the area between your hips (pelvis)
- Lumbar puncture
You have treatment every 3 weeks. During treatment you will have regular blood tests. After you have had 2 cycles of treatment you will have another neurological assessment and an MRI scan. You may also have more eye tests and another lumbar puncture.
After you finish treatment you will see the doctors about 4 weeks later. At this visit you will have a neurological assessment, blood tests and an MRI scan. You will then see the doctors every 3 to 4 months for up to 2 years. At these visits you will have blood tests and a neurological assessment. You will have a CT scan 3 to 4 monthly in the first year and then a final scan at 2 years.
The following are common side effects of thiotepa, ifosfamide, etoposide and rituximab
- An increased risk of getting an infection from a drop in white blood cells. It is harder to fight infections and you can become very ill. You may have headaches, aching muscles, a cough, a sore throat, pain passing urine, or you may feel cold and shivery.
- Tiredness and breathlessness due to a drop in red blood cells (anaemia)
- Bruising easily or bleeding due to a drop in blood cells called platelets. You may have nosebleeds, bleeding gums after brushing your teeth, or lots of tiny red spots or bruises on your arms or legs (known as petechia)
- Tiredness (fatigue) during and after treatment
- Pain in your muscles, joints or bones
- Feeling or being sick
- Diarrhoea or constipation
- Loss of appetite
- A skin rash which may be itchy. This may happen more in areas where you have had radiotherapy
- Sore mouth
- Hair loss
- Confusion, dizziness, problems concentrating, extreme lack of energy (lethargy), anxiety, hallucinations and trouble sleeping
- Hearing problems
- Eye problems (infection, tear duct problems, or cataracts)
- Lung problems (shortness of breath, cough, wheezing or chest pain)
- Irritation of your bladder and kidneys
- Low blood pressure or raised blood pressure
- Changes to the way your liver works
- Changes to the way your kidneys work
- Changes to your heartbeat (arrhythmia)
- A reaction when you have the drugs, causing flu like symptoms such as a fever, chills and shivering (rigors), a headache and feeling sick
- Swelling (often of the face or in the lungs)
- Loss of fertility (ability to have children)
There is also a small increased risk of developing another cancer particularly an acute leukaemia. This happens a number of years after treatment. The study team can tell you more about this and all the side effects associated with treatment in this study.
We have more information about
How to join a clinical trial
Dr Christopher Fox
Experimental Cancer Medicine Centre (ECMC)
University of Birmingham